421 Kipling Street
About Eidos Therapeutics
Eidos Therapeutics is developing a novel treatment for transthyretin (TTR) amyloidosis (ATTR), a progressive, fatal disease affecting multiple organs including the heart and peripheral nerves. Current treatment options focus on managing the symptoms of the conditions, but do not address the underlying cause of the disease: TTR tetramers destabilized by mutations or age. Eidos’ lead compound, AG10, is a small molecule that binds and stabilizes TTR in the blood, preventing the formation of amyloid and potentially halting progression of the disease. Launched in 2016 after years of research supported by Stanford’s TRAM and SPARK programs, Eidos is led by a team of veteran biotechnology executives. Together with patients and physicians, the company aims to provide a safe, effective treatment for ATTR as quickly as possible.
17 articles with Eidos Therapeutics
BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ
Eidos Therapeutics, Inc. announced that the Special Committee of its Board of Directors unanimously rejected the non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder, to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.
Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time
EIDOS THERAPEUTICS INITIATES ATTRIBUTE-CM, A PHASE 3 STUDY OF AG10 IN ATTR-CM WITH REGISTRATIONAL 12-MONTH ENDPOINT
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).
Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy
AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days
FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis
The company plans to initiate Phase 3 studies in each indication in the first half of 2019.
Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced publication of the design and preclinical characterization of its lead product candidate, AG10, in the Journal of Medicinal Chemistry.
6/22/2018Autolus Therapeutics snagged $150 million from its initial public offering, about $25 million more than the company initially expected when it began its roadshow effort earlier this month.
It’s a super-busy week for biotech initial public offerings (IPOs) with six companies raking in a total of around $568 million.
Eidos Therapeutics, Inc. announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $17.00 per share.
On April 5, San Francisco’s Eidos Therapeutics closed on a Series B financing round worth $64 million. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) to raise $115 million through an initial public offering (IPO).
Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.
Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis Cardiomyopathy
Eidos Therapeutics, Inc. announced dosing of the first patient in the Phase 2 clinical trial of AG10 in patients with ATTR cardiomyopathy (NCT03458130).
Eidos Therapeutics closed on a $64 million Series B financing round. The funds will be used to advance the company’s product candidate, AG10, into Phase II clinical trials and Phase III trials.
Funding supports Phase 2 clinical trials of AG10, a potential best-in-class therapy for transthyretin amyloidosis, and ongoing preparation for Phase 3 clinical trials
Preclinical Data Demonstrates Potential of Eidos Therapeutics' Lead Compound for the Treatment for Transythyretin Amyloidosis
These data were shared publicly for the first time yesterday as oral podium presentations at the AHA 2017 Annual Scientific Sessions in Anaheim, CA.
Eidos Therapeutics Initiates First Clinical Study For AG10 Targeting Transthyretin Amyloidosis, Appoints Camille Landis As Chief Business Officer